Viral Vector Formulation, Final Filtration and Filling

Formulation graphic representing downstream gene therapy processing

Formulation, final filtration, and filling are the last steps in viral vector production. A rational formulation design developed by optimizing solution conditions and high-quality excipients can significantly increase viral vector stability and shelf-life. Our wide range of high-quality buffers, salts and stabilizers, low in bioburden and endotoxins, are specifically developed for high-risk applications and can ensure successful downstream processing and formulation of your final gene therapy product.

Designing a successful single-use sterile filtration system should focus on maximizing the recovery of these high-value therapies and consider different filter options, process requirements, sampling needs, and if pre-use post-sterilization integrity testing (PUPSIT) will be performed.

Our Mobius® single-use assemblies offer you flexibility and our specialists can help you design a custom assembly from our broad portfolio of filters and single-use components. These systems are scalable and can be easily replicated to meet your evolving needs.

Supported by our Emprove® program, our excipients, filters and single-use components have extensive documentation, minimizing regulatory and quality-associated risks in your manufacturing. All this simplifies the complexity of your supplier qualification and speeds up processes, thus reducing the total cost of ownership.

  • A broad excipient portfolio, manufactured according to the IPES PQG GMP guidelines
  • Sterilizing-grade filters for viral vector purification
  • Mobius® single-use assemblies for viral vector purification
  • Validation services to confirm your single-use filtration system is suitable for processing

Related Technical Resources


An illustration depicting a healthcare professional in a white coat, presenting a large pink molecule model to a family of three.

Gene Therapy Manufacturing

The rise of gene therapies is driving rapid innovation, but manufacturers face complex challenges bringing new therapies to life

A simplistic purple line drawing of a stylized robot with a rectangular body, two legs, and an antenna on top.

Making the right upstream process decisions not only impacts viral vector titer, but downstream processes, timelines, and regulatory acceptance

A simplistic purple line drawing of a cable car with a square body and a triangular top where the cables are attached.

Efficient virus purification processes can improve yield, decrease time to patient, and lower manufacturing costs

A purple outline of a magnifying glass zooming in on a circuit-like pattern, symbolizing analysis or inspection of technology.

Critical biosafety testing and characterization of viral vector products can help to fully analyze key quality attributes: identity, potency, safety, and stability

A purple outline of a magnifying glass zooming in on a circuit-like pattern, symbolizing analysis or inspection of technology.

CDMO partnerships play a critical role in advancing clinical pipelines and achieving successful commercialization

Related Products

Millipak® Final Fill Filters
Millipak® Final Fill Filters

Millipak® Final Fill capsules are designed for reliable sterile filtration of small volume, high value solutions. 

Durapore® 0.22 µm Capsules
Durapore® 0.22 µm Capsule Filters

Durapore® sterilizing-grade 0.22 µm hydrophilic polyvinylidene fluoride (PVDF) membranes are low protein binding and provide sterility assurance, high flow rates and throughputs.

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?